

RESEARCH ARTICLE

Open Access

Seroprevalence of Cytomegalo Virus (CMV) among pregnant women in Thika, Kenya

Zakayo Maingi² and Anthony Kebira Nyamache^{1*}

Abstract

Background: The fetal consequences of CMV infection have made it one of the most serious infections contracted during pregnancy. Despite the posed teratogenic risk during pregnancy, there is no national screening test for CMV infection is available during pregnancy in Kenya. Thus little is known on its epidemiological data that is necessary for health planners and care providers.

Methods: A cross sectional study was conducted at Thika district level 5 hospital, Kenya to investigate seroprevalence of CMV infections and associated possible risk factors among pregnant women. Structured questionnaires were used to gather socio-demographic data and ELISA was used to detect CMV infections using IgG and IgM.

Results: Out of 260 pregnant women, 201 (77.3%) were CMV IgG 21(8.1%) CMV IgM being on acute stage of the disease. Marital status (OR = 3.7533, 95% CI = 3.0231-6.9631, $P < 0.0001$), parity (OR = 3.7533, 95% CI = 3.0231-6.9631, $P < 0.0001$), and education (OR = 3.7533, 95% CI = 3.0231-6.9631, $P < 0.0001$), history of blood transfusion (OR = 0.0374, 95% CI = 0.00120-0.1168, OR = 0.3804) were found to significantly influence seropositivity in univariate analysis.

Conclusion: The 88.4% CMV prevalence rate being detected among pregnant women calls for vaccine and routine screening for CMV infections and its associated risk factors in this kind of settings.

Background

Cytomegalovirus (CMV) is the commonest among viral infections during perinatal period that cause congenital CMV infections [1]. Its clinical manifestations range from asymptomatic forms (90% of cases) to severe fetal damage that may include permanent hearing, vision loss, neurological impairment and, in rare cases, death due to abortion [2-4]. Previous studies have confirmed that CMV infection is relatively common among women of reproductive age with seroprevalence ranging from 45% to 100%. African continent like South America and Asia has one of the highest prevalence of CMV [4]. From the previous studies conducted in Africa, CMV prevalence rates in Egypt were found to be 96% [5], 85.7% Tanzania [6], 97.2% Benin [7] and 86.4% South Africa [8].

CMV is transmitted from person-to-person via close non-sexual contact, sexual activity, breastfeeding, blood transfusions, and organ transplantation [9]. For pregnant

women, important sources of infection include sexual activity and contact with the urine or saliva of young children, especially their own children [10]. However, seroprevalence varies greatly with a variety of epidemiological factors such as geographical distribution, socio-economic status, marital status and parity [11].

Like other herpes viruses, primary infection is followed with established of lifelong latent infection from which periodic reaction is common [12]. At this stage, symptoms are usually absent including during reaction [13].

As far as prevention is concerned, in addition to health education campaigns, the serological screening of pregnant women has been proposed. However, there is no consensus in the scientific community concerning the implementation of screening and it is not recommended by any public health system despite its teratogenic effects because of its cost/benefit ratio [14]. However, other countries Israel, Belgium, and France their doctors do test their pregnant patients an intervention to CMV infections that should be adopted by all [14].

There is no published data concerning CMV seroprevalence in pregnant women in Kenya. The basic data

* Correspondence: akibera2000@gmail.com

¹Department of Microbiology, Kenyatta University, P.O. Box 43844, 00100 Nairobi, Kenya

Full list of author information is available at the end of the article

concerning CMV infections during pregnancy is important for health planners and care providers. This study was therefore aimed at determining the seroprevalence, associated possible risk factors for CMV infections among pregnant women in Thika Kiambu County.

Methods

To determine the seroprevalence of CMV among the expectant mothers, seeking health services at Thika level 5 hospitals. Consenting pregnant women were approached to participate in the study. A questionnaire was administered and socio-demographic data and blood samples were collected from 260 consenting participants during the period of Sept 2012 to April 2013. The participants were women aged between (18) eighteen years and (45) forty five years old. The participants were sampled from the antenatal clinic. A 5ml blood specimen was obtained for each subject for the evaluation of CMV serum immunoglobulin G antibody using a commercial enzyme-linked immunosorbent assay (Wampole; Inverness Medical Professional Diagnostics) in accordance with the manufacturer's instructions.

Quantitative analysis for CMV (IgG and IgM) was performed, and the assay result interpreted as IU/mL. The manufacturer's instructions were followed for the cut off points, which was <9 IU/mL for CMV IgG and IgM. In cases where samples were tested positive for both IgG and IgM, they further evaluated for the avidity of IgG antibodies. From the analysis, samples that were found to have an avidity index >35% were 43(79.63%) while those detected with <35% were 11(20.37%) indicated IgG, IgM predominance respectively, Table 1.

Statistics

Univariate and multivariate Odd ratio analysis was conducted and on CMV seropostivity for IgG and IgM and its association between IgG, IgM seropostivity and, high parity >4 deliveries, marital status, history of blood transfusion, HIV status, illiteracy, occupation, and residing location determined and *p* values less than 0.05 were considered statistically significant.

Results

Socio-demographic characteristics

A total of 260 pregnant women of the age group of 18–45 years and in their first or second trimesters were

enrolled into this study. The mean age of the participants was 28years with most of the responds being married 168(64.61%) with those divorced being the least 27(10.39%). More than third (39.4%) of these women were literate and either in business 68(26.2%) or employed 70(26.9%). One hundred and thirty seven 137 (53.08%) of the respondents had 1–4 children with most of the participants residing in urban centres 149 (57.3%), Table 2.

CMV seroprevalence

Out of a total of 260 pregnant women under this study, 201(77.3%) and 21(8%) had seropositive CMV IgG and IgM, respectively (Table 2). Those on the age group between 31–35 year old (54), had the highest IgG seropositive rates IgG 46 (85.19%) while those under age 21–25 years old 52 had the least 7(22.26%). However those who were HIV positive (27), had 23(85.2%) IgG seropositive, Table 2.

Risk factors for CMV infections

Multivariate and univariate analysis was used for CMV IgG and IgM seropositive groups as dependent variable and socio-demographic variables as independent variables. *P* value <0.05 was considered significant. We therefore determined if age, high parity >4 deliveries, marital status, history of blood transfusion, HIV status, illiteracy, occupation, and residing location had any significance risk to predict CMV infections. However, marital status, high parity, history of blood transfusion and age were significant risk factors for CMV infection. Geographical location and occupation and HIV status were not significantly associated with CMV infection, Table 2.

Discussion

This is the first published data on the epidemiology of CMV infections among pregnant women in Kenya. Equally few studies have been conducted among pregnant women with most studies being among blood donors. However, in this study, seroprevalence of CMV IgG 77.3% and IgM 8.1% were detected. These findings were similar to those obtained in Sudan (77.2%) [15]. Contrary to previous studies conducted in Africa, higher rates have been reported, in Benin (97.2%) [7], Egypt (96%) [16], Gambia (87%) [17], South Africa (86.4%) [18], Nigeria (100%), [19], 87% [17] Dares Salaam, Tanzania [6] and also in South East Asia [20]. However, in some of European countries, low CMV infection rates have been reported, Australia (56.9%) and France (46.8%) [21]. The low prevalence rates could be due to the inclusion of CMV screening among the antenatal profile tests and better hygienic standards [22]. The low prevalence rates of CMV in this study compared to the rest of the studies in African countries, could be due to diverse HIV infections (which is an

Table 1 Avidity index among participants with both IgM and IgG antibodies

Avidity index	Participants(n)	%
<35%	11	20.37
>35%	43	79.63
Total	54	100.0

Table 2 Socio-demographic characteristics and associated factors with CMV infection of pregnant women in Thika, Kenya

Variable	Participants (n/%)	IgM (n/%)	IgG (n/%)	Univariate	Multivariate
Age group:					
21-25	52(20)	31(12)	7(22.26)		
26-30	95(36)	5(13.68)	77(81.05)	OR = 0.0898	3.3866
31-35	54(21)	2(3.7)	46(85.19)	95% CI = 0.0017-4.4637	0.0665-172.5
36-40	18(7)	4(22.22)	10(55.56)	P = 0.2310	0.5430
41-45	10(4)	1(10)	9(90)		
Subtotal	260	21(8.1)	201(77.1)		
Marital status:					
Single	66(24.39)	9(13.6)	38(57.6)	OR = 3.7533	0.3897
Married	168(64.61)	12(7.2)	137(82)	95% CI = 3.0231-6.9631	0.004-0.0451
Divorced	27(10.39)	0(0)	26(96.3)	P < 0.0001	0.0004
Sub total	260	21	201		
Parity:					
None	117(45)	12(10.35)	76(65.5)	OR = 0.2373	0.2224
One to four	138(53.08)	8(5.8)	121(87.7)	95% CI = 0.1246-0.4519	0.1143-0.5643
>four	5(13.59)	0(0)	4(66.7)	P < 0.0001	P = 0.0003
Sub total	260	20	240		
Trimester of pregnancy:					
First	131(50.4)	9(6.9)	101(77.1)	OR = 1.881	2.3346
Second	129(49.6)	12(9.3)	100(77.5)	95% CI = 0.4448-2.6617	0.8996-3217
Sub total	260	21	201	P = 0.8532	0.7756
Location:					
rural	111(42.7)	9(8.1)	84(75.7)	OR = 0.8509	1.0074
urban	149(57.3)	12(8.1)	117(78.5)	95% CI = 0.4746-1.5256	0.489-2.484
Sub total	260	21	201	P = 0.5878	0.9873
Education:					
None	3(1.2)	0(0)	3(100)	OR = 0.6364	0.427
Primary	12(4.6)	4(33.33)	8(66.7)	95% CI = 0.0318-12.7301	0.0132-13820
Secondary	79(330.4)	9(11.4)	58(73.4)	P = 0.7675	0.1001
Tertiary	166(63.8)	8(4.8)	132(79.5)		
Sub total	260	21	201		
Occupation:					
Business	68(26.2)	5(7.4)	55(80.9)		
Employed	70(26.9)	3(4.3)	58(82.9)	OR 0.6369	1.6143
Housewife	33(12.7)	5(15.2)	26(78.8)	95% CI = 0.2210-1.8359	0.2047-12.7299
Farmer	43(16.5)	3(7.0)	34(79.1)	P = 0.04036	0.6494
Student	46(17.7)	5(10.9)	28(60.9)		
Sub-total	260	21	201		
History of blood transfusion:					
No	243(93.5)	20(8.2)	20(8.2)	OR = 0.0374	2.7125
Yes	17(6.5)	1(5.9)	12(70.6)	95% CI = 0.00120-0.1168	0.0132-0.01382
Sub Total	260	21	32	P < 0.001	P < 0.003

Table 2 Socio-demographic characteristics and associated factors with CMV infection of pregnant women in Thika, Kenya (Continued)

HIV status:					
positive	27(10.3)	1(3.7)	23(85.2)	OR = 0.3804	1.7767
negative	233(89.6)	20(8.6)	178(76.4)	95% CI = -0.0491-2.9448	0.5890-5.3589
Sub total	260	21	201	P = 0.3546	0.3076

Abbreviations: OR Odds Ratio, CI confidence interval.

important coinfections with CMV) [23], diverse socio-demographics, diverse cultures, population behaviour, child cares, breast feeding and sexual activity [24]. The detected 77.3% of CMV infections showed that these women were at high risk of CMV infections.

From this study, we determined the risk factors that could influence HIV infections to CMV infections. From the analysis, women who were married, aged or with high parity, were found to be at higher risk for CMV infection (Table 2). These risk factors were similar to those found by previous studies [15]. These factors increased susceptibility to acquisition of CMV infection, perhaps through the direct contact with contagious secretions from their own children or poor hygiene practiced by these women [25,26]. In addition, in these settings, most women are usually married based on the customs of most African settings with high number of children.

There is a lot of debate concerning maternal age and CMV infection; however most studies including this study have shown elderly women to be at higher risk of CMV infection [27], while others reporting contrary [7,18,27]. However, other factors like geographical location, education and occupation are not significantly associated with CMV infection.

CMV IgG avidity assay seems to be one of the most accessible tools to differentiate between primary from non-primary CMV infection [28]. This technique is less expensive and it could be used to confirming CMV primary infections without the use of sophisticated polymerase chain reactions. In our study, high CMV IgG avidity were confirmed implying that in these women, their pregnancy could be maintained with a lower risk of transmitting CMV infections to their offspring (Table 1) [29]. However, this study was limited with failure to confirm CMV infections by Polymerase Chain Reaction (PCR) including failure to make a follow up of IgM seropositivity women to ascertain their infection status/seroconversion.

Conclusion

This study shows the prevalence of 77.3% similarly to those obtain from other countries with those married aged and with high parity being at a high risk to CMV infections. This study concurs with previous studies that

have suggested all women of the child bearing age to be incorporated in routine antenatal screening profile.

Ethical

This study was approved by Kenyatta University Ethical review committee.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ZM and AKN carried out the study and participated in the statistical analysis and procedures. ZN carried out the practical part of the study. AKN coordinated and participated in the design of the study, statistical analysis and the drafting of the manuscript. Both authors read and approved the final version.

Acknowledgements

The authors would like to thank all the expectant women for participating in this study. The study was funded from the accrued funds generated within the department of Medical laboratory sciences, Kenyatta University.

Author details

¹Department of Microbiology, Kenyatta University, P.O. Box 43844, 00100 Nairobi, Kenya. ²Department of Medical Laboratory Science, Kenyatta University, Nairobi, Kenya.

Received: 10 April 2014 Accepted: 24 October 2014

Published: 12 November 2014

References

- De Paschale M, Agrappi C, Manco MT, Paganini A, Clerici P: Incidence and risk of cytomegalovirus infection during pregnancy in an urban area of Northern Italy. *Infect Dis Obstet Gynecol* 2009, 5. doi:10.1155/2009/206505.
- Alford CA, Stagno S, Pass RF, Britt WJ: Congenital and perinatal cytomegalovirus infections. *Rev Infect Dis* 1990, 12(7):745-753. doi:10.1093/clinids/12.Supplement_7.S745 2.
- Tabatabaee M, Tayyebi D: Seroepidemiologic study of human cytomegalovirus in pregnant women in Valiasr Hospital of Kazeroon, Fars, Iran. *J Matern Fetal Neonatal Med* 2009, 22(6):517-521. doi:10.1080/14767050902801678.
- Cannon MJ, Scott Schmid D, Terri B: Hyde review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev Med Virol* 2010, 20:202-213.
- Kamel N, Metwally L, Gomaa N, Sayed Ahmed WA, Lotfi M, Younis S: Primary cytomegalovirus infection in pregnant Egyptian women confirmed by cytomegalovirus IgG avidity testing. *Med Princ Pract* 2013, doi:10.1159/000354758.
- Mhalu F, Haukenes G: Prevalence of cytomegalovirus antibody in pregnant women, AIDS patients and STD patients in Dar es Salaam. *AIDS* 1990, 4(12):1294-1295.
- Rodier MH, Berthonneau J, Bourgoin A, Giraudeau G, Agius G, Burucoa C, Hekpazo A, Jacquemin JL: Seroprevalences of Toxoplasma, malaria, rubella, cytomegalovirus, HIV and treponemal infections among pregnant women in Cotonou, Republic of Benin. *Acta Trop* 1995, 59(4):271-277.

8. Bos P, Steele AD, Peenze I, Aspinall S: **Sero-prevalence to hepatitis B and C virus infection in refugees from Mozambique in southern Africa.** *East Afr Med J* 1995, **72**(2):113–115.
9. Stagno S: **Cytomegalovirus.** In *Infectious Diseases of the Fetus and Newborn Infant*. Edited by Remington JS, Klein JO. Philadelphia: W.B. Saunders Company; 2001:389–424.
10. Pass RF, Hutto C, Ricks R, Cloud GA: **Increased rate of cytomegalovirus infection among parents of children attending daycare centers.** *N Engl J Med* 1986, **314**:1414–1418.
11. Bawaraju A, Mane PM, Vijayadurga S: **The reactivation of the cytomegalovirus (CMV) infection in HIV infected patients.** *J of Clinical and Diagnostic Research* 2011, **5**(4):749–751.
12. Rautemaa R, Helander T, Meri S: **Herpes simplex virus 1 infected neuronal and skin cells differ in their susceptibility to complement attack.** *Immunology* 2002, **106**(3):404–411.
13. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ: **Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity.** *N Engl J Med* 2001, **344**:1366–1371.
14. Revello MG, Gerna G: **Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.** *Clin Microbiol Rev* 2002, **15**(4):680–715.
15. Hamdan HZ, Abdelbagi IE, Nasser NM, Adam I: **Seroprevalence of cytomegalovirus and rubella among pregnant women in Western Sudan.** *Virol J* 2011, **8**:217.
16. el-Nawawy A, Soliman AT, El Azzouni O, Amer e-S, Karim MA, Demian S, el-Sayed M: **Maternal and neonatal prevalence of toxoplasma and cytomegalovirus (CMV) antibodies and hepatitis-B antigens in an Egyptian rural area.** *J Trop Pediatr* 1996, **42**(3):154–157. doi:10.1093/tropej/42.3.154.
17. Bello C, Whittle H: **Cytomegalovirus infection in Gambian mothers and their babies.** *J Clin Pathol* 1991, **44**(5):366–369. doi:10.1136/jcp.44.5.366.
18. Schoub BD, Johnson S, McAnerney JM, Blackburn NK, Guidozzi F, Ballot D, Rothberg A: **Is antenatal screening for rubella and cytomegalovirus justified?** *S Afr Med J* 1993, **83**(2):108–110.
19. Williams JO, Fagbami AH, Omilabu SA: **Cytomegalovirus antibodies in Nigeria.** *Trans R Soc Trop Med Hyg* 1989, **83**(2):260.
20. Taechowisan T, Sutthent R, Louisirirochanakul S, Puthavathana P, Wasi C: **Immune status in congenital infections by TORCH agents in pregnant Thais.** *Asian Pac J Allergy Immunol* 1997, **15**(2):93–97.
21. Picone O, Vauloup-Fellous C, Cordier AG: **A 2-year study on cytomegalovirus infection during pregnancy in a French hospital.** *BJOG* 2009, **116**:818.
22. Guerra B, Simonazzi G, Banfi A, Lazzarotto T, Farina A, Lanari M, Rizzo N: **Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers.** *AJOG* 2007, **196**:221.e1–6.
23. Fabiani M, Nattabi B, Opio AA, Musinguzi J, Biryahwaho B, Ayella EO, Ogwang M, Declich S: **A high prevalence of HIV-1 infection among pregnant women living in a rural district of North Uganda severely affected by civil strife.** *Trans Roy Soc Trop Med Hyg* 2006, **100**(6):586–593. doi:10.1016/j.trstmh.2005.09.002.
24. Peckham CS, Johnson C, Ades A, Pearl K, Chin KS: **Early acquisition of cytomegalovirus infection.** *Arch Dis Child* 1987, **62**(8):780–785. doi:10.1136/adc.62.8.780.
25. Kramer A, Schwebke I, Kampf G: **How long do nosocomial pathogens persist on inanimate surfaces? A systematic review.** *BMC Infect Dis* 2006, **6**:130. doi:10.1186/1471-2334-6-130 28.
26. Bate SL, Dollard SC, Cannon MJ: **Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004.** *Clin Infect Dis* 2010, **50**(11):1439–1447. doi:10.1086/652438.
27. Bukbuk DN, el Nafaty AU, Obed JY: **Prevalence of rubella-specific IgG antibody in non-immunized pregnant women in Maiduguri, north eastern Nigeria.** *Cent Eur J Public Health* 2002, **10**(1–2):21–23.
28. Luerez- Ville M, Seller Y, Salomon LJ, Stirnemann JJ, Jacquemard F, Ville Y: **Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy, a retrospective cohort.** *Clinical infection Dis* 2013, **56**:1428–1435.
29. Duff P: **A Thoughtful algorithm for the accurate diagnosis of primary CMV infection in pregnancy.** *Obstet Gynaec* 2007, **196**:196–197.

doi:10.1186/1756-0500-7-794

Cite this article as: Maingi and Nyamache: Seroprevalence of Cytomegalovirus (CMV) among pregnant women in Thika, Kenya. *BMC Research Notes* 2014 **7**:794.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

